Compare Neurocrine Biosciences Inc (NBIX) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Trade Desk Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Trade Desk Inc trades at $18.27 (market cap $8.76B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | TTD | |
|---|---|---|
Market Cap | $17.40B | $8.76B |
Sector | Health | Technology |
52-Week High | $180.55 | $89.76 |
52-Week Low | $123.10 | $17.33 |
Enterprise Value | $16.49B | $7.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
The Trade Desk (TTD) trades at $18.25, down 1.83% with bearish technical signals. Revenue grew to $2.9B in 2025 with strong 77.8% gross margins, though Q1 2026 EPS missed expectations. Recent executive appointments and the Publicis dispute settlement provide operational stability. The stock faces headwinds from slowing growth and competitive pressure from tech giants.
TTD presents a value opportunity at 21x P/E with 49% analyst buy ratings and $25.23 price target upside. Risks include persistent revenue deceleration and market share loss to walled gardens. The company's profitability and strategic partnerships support long-term potential despite near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
